VENUS MEDTECH-B (02500) Rises Over 4% as Tricuspid Valve Replacement Product Cardiovalve Submits EU CE Mark Application

Stock News2025-12-24

VENUS MEDTECH-B (02500) surged over 4%, reaching HK$2.48 by the time of writing, with a trading volume of HK$1.1562 million. The company announced that it has formally submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to a European notified body. This marks a critical step toward the product's market entry in Europe.

The Cardiovalve System is a transcatheter intervention product designed to treat both mitral and tricuspid regurgitation. Compared to similar products, its transfemoral venous approach significantly enhances treatment safety. With a large annulus design of up to 55mm, it accommodates approximately 95% of patients. Additionally, its unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System is simple, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and deployment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149691374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149691374","market":"hk","top_or_hot":-1,"title":"VENUS MEDTECH-B (02500) Rises Over 4% as Tricuspid Valve Replacement Product Cardiovalve Submits EU CE Mark Application","media":"Stock News","content":"<p>VENUS MEDTECH-B (02500) surged over 4%, reaching HK$2.48 by the time of writing, with a trading volume of HK$1.1562 million. The company announced that it has formally submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to a European notified body. This marks a critical step toward the product's market entry in Europe.</p>\n<p>The Cardiovalve System is a transcatheter intervention product designed to treat both mitral and tricuspid regurgitation. Compared to similar products, its transfemoral venous approach significantly enhances treatment safety. With a large annulus design of up to 55mm, it accommodates approximately 95% of patients. Additionally, its unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System is simple, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and deployment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VENUS MEDTECH-B (02500) Rises Over 4% as Tricuspid Valve Replacement Product Cardiovalve Submits EU CE Mark Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVENUS MEDTECH-B (02500) Rises Over 4% as Tricuspid Valve Replacement Product Cardiovalve Submits EU CE Mark Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-24 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VENUS MEDTECH-B (02500) surged over 4%, reaching HK$2.48 by the time of writing, with a trading volume of HK$1.1562 million. The company announced that it has formally submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to a European notified body. This marks a critical step toward the product's market entry in Europe.</p>\n<p>The Cardiovalve System is a transcatheter intervention product designed to treat both mitral and tricuspid regurgitation. Compared to similar products, its transfemoral venous approach significantly enhances treatment safety. With a large annulus design of up to 55mm, it accommodates approximately 95% of patients. Additionally, its unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System is simple, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and deployment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1149691374","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149691374","pubTimestamp":1766544014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VENUS MEDTECH-B (02500) surged over 4%, reaching HK$2.48 by the time of writing, with a trading volume of HK$1.1562 million. The company announced that it has formally submitted the complete...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","02500":"启明医疗-B","CE":"塞拉尼斯","BK1583":"高瓴概念","BK4109":"特种化学制品","BK1100":"医疗保健设备","BK4588":"碎股"},"translate_title":"启明星辰医疗-B(02500)涨超4%，因三尖瓣置换产品Cardiovalve提交欧盟CE标志申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CE":1,"FESXmain":1,"FSXEmain":1,"02500":1},"content_text":"VENUS MEDTECH-B (02500) surged over 4%, reaching HK$2.48 by the time of writing, with a trading volume of HK$1.1562 million. The company announced that it has formally submitted the complete application for CE MDR certification of its Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve System) to a European notified body. This marks a critical step toward the product's market entry in Europe.\nThe Cardiovalve System is a transcatheter intervention product designed to treat both mitral and tricuspid regurgitation. Compared to similar products, its transfemoral venous approach significantly enhances treatment safety. With a large annulus design of up to 55mm, it accommodates approximately 95% of patients. Additionally, its unique short-frame design effectively reduces the risk of ventricular outflow tract obstruction. The Cardiovalve System is simple, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and deployment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149691374","isCrawlerRequest":true}